The SMILE-100 System is a breast thermography device that helps healthcare personnel review, measure and analyze thermally significant indications in the breast region
The breakthrough approval expands the existing indication of Jardiance to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that previously had no approved therapies in Europe
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Brian joins LEO Pharma from Novo Nordisk, U.S. where he served as Senior Vice President of Sales.
Key takeaways of Q3FY22 quarter & conference call highlights
Adds five years of market exclusivity on approval
Vabysmo is the only injectable eye medicine approved simultaneously in the US for wet AMD and DME, with flexible dosing regimens based on patient need
The company has been manufacturing masks since the Covid-19 outbreak in 2020
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
This surpasses the number of approvals supported in 2020
Subscribe To Our Newsletter & Stay Updated
